Keryx Biopharma (KERX) Misses Q1 EPS by 1c, Beat on Revenues

Keryx Biopharma (NASDAQ: KERX) reported Q1 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $10.27 million.

2017 Financial Guidance

Keryx today provided financial guidance for full year 2017 net U.S. Auryxia product sales of $56 to $60 million. The guidance is based on the company’s current understanding of Auryxia prescriptions trends in dialysis. Guidance excludes potential sales from the potential approval in November 2017 of ferric citrate in the U.S. for the treatment of adults with NDD-CKD and iron deficiency anemia.

Highlights

• Company reported $11.8 million in first quarter 2017 total revenue, including net U.S. Auryxia® (ferric citrate) product sales of $10.5 million
• Provides 2017 net U.S. Auryxia product sales guidance of $56 to $60 million
• Target action date of November 6, 2017 set for supplemental new drug application (sNDA) to expand indication of ferric citrate; Expanded indication would leverage reimbursement access, awareness and existing infrastructure

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c